-
12/11/2025 iPADTERNEW PLATFORM FOR THE PRODUCTION OF ADVANCED THERAPY MEDICINAL PRODUCTS USING INDUCED PLURIPOTENT STEM CELLS...
-
20/10/2025 REPROCELL and Histocell Achieve GMP Certification for Manufacturing Process of Clinical-Grade iPSC Master and Working Cell Banks Using StemRNA™ Clinical iPSCsREPROCELL (Yokohama, Japan; TYO: 4978) and Histocell (Bilbao, Spain) are proud to announce that the...
-
10/05/2024 Histocell receives the “Enpresan Bardin” award from CEBEK for its equality policies.On May 8, Histocell received the "Enpresan Bardin" award for its work in equality during...
-
25/01/2024 Histocell obtains AEMPS authorisation and GMP certification for its new manufacturing plant for cell therapy and associated biological medicinal products in Larrabetzu.The biopharmaceutical company reaffirms its commitment to local innovation and manufacturing with the extension of...
-
24/05/2023 REPROCELL offers mesenchymal stem cell based CDMO services to manufacture Advanced Therapies Medicinal ProductsYokohama Japan, 24 May 2023 REPROCELL will now offer CDMO services to manufacture Advanced Therapies...
-
17/01/2023 Histocell takes part in the new European project NABIHEAL in biomaterials for complex wound healingThe Horizon Europe project NABIHEAL, coordinated by the Center for Biomedical Research Network (CIBER) at...
-
09/01/2023 FORCE REPAIRCURRENT PROJECTS FORCE REPAIR January 2023 - December 2026 Grant agreement: 101092243 “SMART AND MULTIFUNCTIONAL...
-
09/01/2023 NABIHEALCURRENT PROJECTS NABIHEAL January 2023 - December 2026 Grant Agreement: 101092269 "ANTIMICROBIAL NANOSTRUCTURED BIOMATERIALS FOR...
-
19/12/2022 Histocell leads ITEAS project: industrial research to boost advanced therapies in the Basque CountryThe ITEAS project investigates advanced therapy drugs to generate new therapeutic strategies for their application...
-
23/11/2022 Japanese company REPROCELL invests in HistocellREPROCELL Inc. decided to invest in Histocell S.L. to strengthen its clinical induced pluripotent stem...
